MedPath

Stent Retriever Versus Contact Aspiration in Irregular Occlusion Phenotype

Not Applicable
Recruiting
Conditions
Stroke, Acute
Interventions
Procedure: stent retriever thrombectomy
Procedure: contact aspiration thrombectomy
Registration Number
NCT05595876
Lead Sponsor
Hopital Foch
Brief Summary

Patients with a clinico-neuroradiological mismatch pattern shown on the magnetic resonance imaging/Computed Tomography in the acute phase of stroke are more likely to benefit from reperfusion, are suitable candidates for endovascular therapy, and have a better clinical prognosis.

The ASTER Trial showed similar results between stent-retrievers and contact aspiration concerning the recanalization grade in anterior circulation occlusions. However, we still observe late and futile recanalizations, secondary either to extended ischemic lesions at baseline, long-time procedures or intraprocedural complications. The First Pass Effect that is the complete/nearly complete recanalization after the first maneuver, independently on the technique used, has been strongly associated with better clinical outcomes . In a recent paper we proposed a novel approach to identify those cases that could be treated with a specific technique (stent-retriever) with higher chances to achieve a complete or nearly complete recanalization, with lower procedure times and lower complication rates. This approach is focused on the identification of a regular or irregular phenotype of the occlusion site in patients with an M1-Middle Cerebral Artery occlusion. The phenotype is defined as "regular" whether the profile of the occlusion is abruptly cut without any irregularity and as "irregular" if any irregularity of the profile of the occlusion is observed. One of the hypotheses that could explain these results could be related to the composition of the clot : a soft and less organized clot could be more easily flattened by the pulsatile flow and therefore determine a regular aspect of the occlusion. A more solid and organized clot would, on the contrary, maintain an irregular profile because it would not be flattened by the blood flow and the contrast medium could highlight the irregularities of the proximal face of the clot.

The latter could be a favorable target for the use of a stent-retriever since the interaction between a solid clot and the struts of the stent could increase the chance to retrieve the clot. Therefore, we propose this randomized controlled trial to assess the superiority of stent-retrievers compared to contact aspiration in the treatment of irregular phenotype occlusions of the M1-Middle Cerebral Artery.

Detailed Description

Statistical analyses will be independently performed by the Biostatistics Department of University of Lille under the responsibility of Julien Labreuche. Data will be analyzed using the SAS software (SAS Institute Inc, Cary, NC, USA). A detailed statistical analysis plan will be written and finalized prior to the database lock. Baseline characteristics will be described for each group. Quantitative variables will be expressed as mean (standard deviation) or median (interquartile range) for non-Gaussian distribution. Qualitative variables will be expressed as frequencies and percentages. Normality of distribution will be assessed graphically and using the Shapiro-Wilk test. All applicable statistical tests will be 2-sided and no correction for multiple comparisons will be applied; all secondary objectives will be considered as exploratory and results were reported with only effect size estimates with their confidence intervals (CIs). All CIs presented will be 95%CI and 2-sided. The final report will be written, based on the CONSORT statement recommendations.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
356
Inclusion Criteria
  • Age ≥ 18 years
  • M1-Middle Cerebral Artery occlusion
  • Eligible for mechanical thrombectomy: groin puncture performed within 24 hours from the first symptoms or from the last time the patient was seen normal.
  • Presence of a mismatch on Magnetic resonance imaging MRI or CT (computed tomography) scan
  • Baseline mRS <2
  • Irregular occlusion phenotype on the first angiographic run
  • Informed consent obtained from the patients/his proxy or following an emergency procedure
  • Being covered by a national health insurance
Read More
Exclusion Criteria
  • Isolated M2 occlusions
  • Clinical history, past imaging or clinical judgment suggesting underlying intracranial stenosis
  • Severe contrast medium allergy or absolute contraindication to use of iodinated products
  • Patients with severe or fatal comorbidities that will likely prevent improvement or follow-up, or that will render the procedure unlikely to benefit the patient
  • Angiographic evidence of carotid dissection or tandem cervical occlusion or stenosis requiring treatment
  • Pregnancy (urine or serum beta HCG test for women of child-bearing potential)
  • Patient benefiting from a legal protection (guardianship or curatorship)
  • Being deprived of liberty
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Stent retrieverstent retriever thrombectomyThe patients will be treated to receive stent retriever (with or without contact aspiration) first line thrombectomy (experimental arm).
Contact aspirationcontact aspiration thrombectomyThe patients will be treated to receive direct contact aspiration first line thrombectomy (control arm)
Primary Outcome Measures
NameTimeMethod
Rate of favorable functional outcome at 90-day defined by a Modified Rankin Scale (mRS) 0-23 months

mRS is evaluated between 0 to 6. A score of 0 indicates that there is no disability and a score of 6 indicates death

Secondary Outcome Measures
NameTimeMethod
Rate of patients with first pass effect (FPE) defined as mTICI 2c/3 after first device maneuver24 hours

The definition of FPE: single pass/use of the device, (2) complete revascularization of the large vessel occlusion and its downstream territory (mTICI 3), and (3) no use of rescue therapy

Rate of patients who will require less than 2 device pass24 hours

Rate of patients who require less than 2 devices pass

Rate of patients with rescue therapy use24 hours

Rate of patient with other than one pass with thrombectomy device

Incidence of procedure-related complications such as arterial perforation or dissection, embolization in new territory48 hours

arterial perforation or dissection, embolization in new territory

Rates of patients with complete (mTICI 3), perfect (mTICI 2c/3) and successful reperfusion (mTICI 2b/3) at the end of endovascular procedure24 hours

mTICI (modified Thrombolysis In Cerebral Infarction ) score equals to 3 after the first line thrombectomy and at the end of endovascular.

mTICI score is evaluated between 0-3 : 0 a complete obstruction of the artery and 3 indicates a complete reperfusion

Time from groin puncture to achieve the maximum recanalization24 hours

The time between the groin puncture and the maxiamum recanalization will be assessed

Degree of disability assessed by overall distribution of the mRS at 90 days and one year (shift analysis combining scores of 5 and 6)12 months

overall distribution of the mRS at 90 days and one year

Rate of all-cause mortality at 90 day and one year12 months

number of mortality at 90 days and on year

24 hours change in NIHSS from baseline defined as the difference between NIHSS score at 24 hours and NIHSS score at admission24 hours

NIHSS (National Institutes of Health Stroke Scale) score is evaluated between 0-42 0 is normal and 42 maximal gravity

Incidence of intracerebral haemorrhage (ICH), parenchymal hematoma, symptomatic ICH, on brain imaging (Magnetic resonance imaging MRI or CT (computed tomography) scan) at 24 hours after thrombectomy (according to ECASS3 classification)24 hours

ECASS III (European Cooperative Acute Stroke Study) classification :

* Hemorrhage infarction type 1 (HI1)

* Hemorrhage infarction type 2 (HI2)

* Parenchymal hematoma type 1 (PH1)

* Parenchymal hematoma type 2 (PH2)

Trial Locations

Locations (9)

Chu Bordeaux

🇫🇷

Bordeaux, France

CHU Montpellier

🇫🇷

Montpellier, France

Chu Nantes

🇫🇷

Nantes, France

Chru Nancy

🇫🇷

Nancy, France

CHU de Reims

🇫🇷

Reims, France

APHP - Pitié Salpêtrière

🇫🇷

Paris, France

Fondation Adolphe de Rothschild

🇫🇷

Paris, France

Hôpital FOCH

🇫🇷

Suresnes, France

CHU de Tours

🇫🇷

Tours, France

© Copyright 2025. All Rights Reserved by MedPath